TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07759245: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstruct

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 606 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,806,000

Rescue Site Savings

+$4,482,000

Unlock Full NCT07759245 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07759245 Rescue Dossier →